상세 보기
- Yoon, Seug Yun;
- Yoon, Sung-Soo;
- Yang, Deok-Hwan;
- Lee, Gyeong-Won;
- Sohn, Sang Kyun;
- 외 10명
WEB OF SCIENCE
0SCOPUS
0초록
Background: Polycythemia vera (PV) is a myeloproliferative neoplasm driven by JAK2 V617F mutations. Ropeginterferon alfa-2b effectively reduces both hematologic parameters and JAK2 allele burden, but molecular monitoring is not always readily available. Objectives: To evaluate whether a >= 50% reduction in the neutrophil-to-lymphocyte ratio (NLR) can serve as a surrogate marker of hematologic and molecular response during ropeginterferon therapy. Design: Secondary analysis of a multicenter, phase II, open-label trial in South Korea. Methods: Ninety-five patients with PV received ropeginterferon alfa-2b biweekly for 48 weeks. NLR and JAK2 allele burden were serially measured, and generalized estimating equations and logistic regression were used to assess associations. Results: NLR half reduction significantly predicted hematologic response (week 24 OR 6.42, p = 0.001) and molecular response consistently across all time points (week 24 OR 27.94, p < 0.001). Conclusion: NLR half reduction is a simple, cost-effective biomarker that may reflect molecular response and treatment efficacy in PV.
키워드
- 제목
- Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b
- 저자
- Yoon, Seug Yun; Yoon, Sung-Soo; Yang, Deok-Hwan; Lee, Gyeong-Won; Sohn, Sang Kyun; Shin, Ho-Jin; Bae, Sung Hwa; Choi, Chul Won; Choi, Eun-Ji; Cheong, June-Won; Bang, Soo-Mee; Park, Joon Seong; Park, Yong; Park, Young Hoon; Lee, Sung-Eun
- 발행일
- 2026-03
- 유형
- Article
- 권
- 17